CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and complex class of genetic ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...